Company Shows Another Year of Record Growth and Advancements State College, PA (29 January 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2019. With final numbers to be released to Company Shareholders in the upcoming weeks,Read More
INDIGO Expands Discovery Platform to Include Zebrafish Assays
Expansion Meets Industry Demand for Pre-Clinical Models for Cancer and Environmental Research State College, PA (23 January 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio. These additions both expand INDIGO’s robust portfolio of in vitro animal model assay systems andRead More
INDIGO Biosciences Welcomes New Member to Board of Directors
Mark McLoughlin Brings Four Decades of Healthcare Industry Experience to the Company’s Board State College, PA (13 August 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin to the Company’s Board of Directors. Mark brings four decades of healthcare industry experience to theRead More
INDIGO Biosciences Announces Release of Assay Kit for Testing Multi-Drug Resistance
Testing Allows Researchers to Determine Possibility of Drug-Drug Interactions Before Clinical Trials State College, PA (19 June 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’sRead More